Cargando…

A subunit vaccine against pneumonia: targeting Streptococcus pneumoniae and Klebsiella pneumoniae

Community-acquired pneumonia is primarily caused by Streptococcus pneumoniae and Klebsiella pneumoniae, two pathogens that have high morbidity and mortality rates. This is largely due to bacterial resistance development against current antibiotics and the lack of effective vaccines. The objective of...

Descripción completa

Detalles Bibliográficos
Autores principales: Rafi, Md. Oliullah, Al-Khafaji, Khattab, Mandal, Santi M., Meghla, Nigar Sultana, Biswas, Polash Kumar, Rahman, Md. Shahedur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115389/
https://www.ncbi.nlm.nih.gov/pubmed/37096010
http://dx.doi.org/10.1007/s13721-023-00416-3
_version_ 1785028203532779520
author Rafi, Md. Oliullah
Al-Khafaji, Khattab
Mandal, Santi M.
Meghla, Nigar Sultana
Biswas, Polash Kumar
Rahman, Md. Shahedur
author_facet Rafi, Md. Oliullah
Al-Khafaji, Khattab
Mandal, Santi M.
Meghla, Nigar Sultana
Biswas, Polash Kumar
Rahman, Md. Shahedur
author_sort Rafi, Md. Oliullah
collection PubMed
description Community-acquired pneumonia is primarily caused by Streptococcus pneumoniae and Klebsiella pneumoniae, two pathogens that have high morbidity and mortality rates. This is largely due to bacterial resistance development against current antibiotics and the lack of effective vaccines. The objective of this work was to develop an immunogenic multi-epitope subunit vaccine capable of eliciting a robust immune response against S. pneumoniae and K. pneumoniae. The targeted proteins were the pneumococcal surface proteins (PspA and PspC) and choline-binding protein (CbpA) of S. pneumoniae and the outer membrane proteins (OmpA and OmpW) of K. pneumoniae. Different computational approaches and various immune filters were employed for designing a vaccine. The immunogenicity and safety of the vaccine were evaluated by utilizing many physicochemical and antigenic profiles. To improve structural stability, disulfide engineering was applied to a portion of the vaccine structure with high mobility. Molecular docking was performed to examine the binding affinities and biological interactions at the atomic level between the vaccine and Toll-like receptors (TLR2 and 4). Further, the dynamic stabilities of the vaccine and TLRs complexes were investigated by molecular dynamics simulations. While the immune response induction capability of the vaccine was assessed by the immune simulation study. Vaccine translation and expression efficiency was determined through an in silico cloning experiment utilizing the pET28a(+) plasmid vector. The obtained results revealed that the designed vaccine is structurally stable and able to generate an effective immune response to combat pneumococcal infection. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13721-023-00416-3.
format Online
Article
Text
id pubmed-10115389
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-101153892023-04-20 A subunit vaccine against pneumonia: targeting Streptococcus pneumoniae and Klebsiella pneumoniae Rafi, Md. Oliullah Al-Khafaji, Khattab Mandal, Santi M. Meghla, Nigar Sultana Biswas, Polash Kumar Rahman, Md. Shahedur Netw Model Anal Health Inform Bioinform Original Article Community-acquired pneumonia is primarily caused by Streptococcus pneumoniae and Klebsiella pneumoniae, two pathogens that have high morbidity and mortality rates. This is largely due to bacterial resistance development against current antibiotics and the lack of effective vaccines. The objective of this work was to develop an immunogenic multi-epitope subunit vaccine capable of eliciting a robust immune response against S. pneumoniae and K. pneumoniae. The targeted proteins were the pneumococcal surface proteins (PspA and PspC) and choline-binding protein (CbpA) of S. pneumoniae and the outer membrane proteins (OmpA and OmpW) of K. pneumoniae. Different computational approaches and various immune filters were employed for designing a vaccine. The immunogenicity and safety of the vaccine were evaluated by utilizing many physicochemical and antigenic profiles. To improve structural stability, disulfide engineering was applied to a portion of the vaccine structure with high mobility. Molecular docking was performed to examine the binding affinities and biological interactions at the atomic level between the vaccine and Toll-like receptors (TLR2 and 4). Further, the dynamic stabilities of the vaccine and TLRs complexes were investigated by molecular dynamics simulations. While the immune response induction capability of the vaccine was assessed by the immune simulation study. Vaccine translation and expression efficiency was determined through an in silico cloning experiment utilizing the pET28a(+) plasmid vector. The obtained results revealed that the designed vaccine is structurally stable and able to generate an effective immune response to combat pneumococcal infection. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13721-023-00416-3. Springer Vienna 2023-04-19 2023 /pmc/articles/PMC10115389/ /pubmed/37096010 http://dx.doi.org/10.1007/s13721-023-00416-3 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article
Rafi, Md. Oliullah
Al-Khafaji, Khattab
Mandal, Santi M.
Meghla, Nigar Sultana
Biswas, Polash Kumar
Rahman, Md. Shahedur
A subunit vaccine against pneumonia: targeting Streptococcus pneumoniae and Klebsiella pneumoniae
title A subunit vaccine against pneumonia: targeting Streptococcus pneumoniae and Klebsiella pneumoniae
title_full A subunit vaccine against pneumonia: targeting Streptococcus pneumoniae and Klebsiella pneumoniae
title_fullStr A subunit vaccine against pneumonia: targeting Streptococcus pneumoniae and Klebsiella pneumoniae
title_full_unstemmed A subunit vaccine against pneumonia: targeting Streptococcus pneumoniae and Klebsiella pneumoniae
title_short A subunit vaccine against pneumonia: targeting Streptococcus pneumoniae and Klebsiella pneumoniae
title_sort subunit vaccine against pneumonia: targeting streptococcus pneumoniae and klebsiella pneumoniae
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115389/
https://www.ncbi.nlm.nih.gov/pubmed/37096010
http://dx.doi.org/10.1007/s13721-023-00416-3
work_keys_str_mv AT rafimdoliullah asubunitvaccineagainstpneumoniatargetingstreptococcuspneumoniaeandklebsiellapneumoniae
AT alkhafajikhattab asubunitvaccineagainstpneumoniatargetingstreptococcuspneumoniaeandklebsiellapneumoniae
AT mandalsantim asubunitvaccineagainstpneumoniatargetingstreptococcuspneumoniaeandklebsiellapneumoniae
AT meghlanigarsultana asubunitvaccineagainstpneumoniatargetingstreptococcuspneumoniaeandklebsiellapneumoniae
AT biswaspolashkumar asubunitvaccineagainstpneumoniatargetingstreptococcuspneumoniaeandklebsiellapneumoniae
AT rahmanmdshahedur asubunitvaccineagainstpneumoniatargetingstreptococcuspneumoniaeandklebsiellapneumoniae
AT rafimdoliullah subunitvaccineagainstpneumoniatargetingstreptococcuspneumoniaeandklebsiellapneumoniae
AT alkhafajikhattab subunitvaccineagainstpneumoniatargetingstreptococcuspneumoniaeandklebsiellapneumoniae
AT mandalsantim subunitvaccineagainstpneumoniatargetingstreptococcuspneumoniaeandklebsiellapneumoniae
AT meghlanigarsultana subunitvaccineagainstpneumoniatargetingstreptococcuspneumoniaeandklebsiellapneumoniae
AT biswaspolashkumar subunitvaccineagainstpneumoniatargetingstreptococcuspneumoniaeandklebsiellapneumoniae
AT rahmanmdshahedur subunitvaccineagainstpneumoniatargetingstreptococcuspneumoniaeandklebsiellapneumoniae